ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Xenogeneic Mitochondrial Transplantation Improves Selected Age-Associated Phenotypes in Mice.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Xenogeneic mitochondrial transplantation (xeno-MT) improves selected age-associated phenotypes and mitochondrial functional readouts in mice while engaging host mitochondrial quality-control-related pathways. Donor mitochondrial preparations with impaired membrane potential retained measurable activity, but both respiratory competence and in vivo efficacy declined progressively with more extensive room-temperature damage and were largely lost after complete disruption. Although beneficial effects were observed in additional donor contexts, the present study provides the most detailed in vivo evidence for yak-derived xeno-MT, and broader donor equivalence remains to be established. These findings support xeno-MT as proof-of-concept evidence of biological activity and short-term tolerability under the conditions tested, while long-term safety, germline relevance, and pathway-specific dependence remain to be defined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.